Come Friday morning, Amgen will reveal whether its costly, much-discussed new cholesterol drug will live up to blockbuster expectations — or become a cautionary tale in biopharma lore.
At the American Cardiology Conference in Washington, D.C., Amgen will present results from a 27,000-patient study determining whether its drug can reduce patients’ risk of heart attack and stroke, with sweeping ramifications for payers, patients, investors, and pharma.
“This trial has the potential to be truly game-changing,” said Dr. Jeffrey Kuvin, a Tufts University cardiologist who serves as a chair of ACC.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect